Fitness landscape of substrate-adaptive mutations in evolved APC transporters

Foteini Karapanagioti[1], Úlfur Á. Atlason[1], Dirk J. Slotboom[1*], Bert Poolman[1*] and Sebastian Obermaier[1*]

[1]Department of Biochemistry, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands

[*]Corresponding authors: DJS (d.j.slotboom@rug.nl), BP (b.poolman@rug.nl) or SO (s.obermaier@protonmail.com)

Keywords: Amino acid-Polyamine-organoCation transport family, amino acid transport, experimental evolution, yeast, *Saccharomyces cerevisiae*, adaptive mutations

Abstract

The emergence of new protein functions is crucial for the evolution of organisms. This process has been extensively researched for soluble enzymes, but it is largely unexplored for membrane transporters, even though the ability to acquire new nutrients from a changing environment requires evolvability of transport functions. Here, we demonstrate the importance of environmental pressure in obtaining a new activity or altering a promiscuous activity in members of the Amino acid-Polyamine-organoCation (APC)-type yeast amino acid transporters family. We identify APC members that have broader substrate spectra than previously described. Using *in vivo* experimental evolution, we evolve two of these transporter genes, *AGP1* and *PUT4*, towards new substrate specificities. Single mutations on these transporters are found to be sufficient for expanding the substrate range of the proteins, while retaining the capacity to transport all original substrates. Nonetheless, each adaptive mutation comes with a distinct effect on the fitness for each of the original substrates, illustrating a trade-off between the ancestral and evolved functions. Collectively, our findings reveal how substrate-adaptive mutations in membrane transporters contribute to fitness and provide insights into how organisms can use transporter evolution to explore new ecological niches.

Introduction

Life continuously creates genetic innovation, e.g., genes coding for proteins with novel functions. Most new genes emerge by modification of existing genes rather than *de novo* [1]. The first who connected the generation of new functions with the accumulation of mutations and duplication of pre-existing genes was Müller [2]. Later on, different theories arose discussing the point at which divergence takes place [3–6]. Modern evolutionary models assume an ancestral gene to acquire a novel function while retaining its original function [6–10]. If a novel function is beneficial for the organism, the gene variant is subjected to positive

selection. Consecutive duplication of the gene allows the establishment of the new function in the population. This model of divergence prior to gene duplication allows for the accumulation and selection of mutations with adaptive potential while the original gene function is maintained, thus creating a 'generalist' gene with multiple functions [11].

When considering the evolution of novel gene functions, the substrate range of 'classical', soluble enzymes is arguably the most archetypal field of study, important for the rapid evolution of antibiotic resistance, degradation of artificial xenobiotics, or use of new nutrients [8, 12]. The substrate spectrum of an enzyme is often a key determinant of the fitness of an organism. Generally, enzymes are thought of as being highly specific for a certain substrate or a group of chemically similar substrates. Nonetheless, many enzymes studied in isolation show side activities towards other substrates [12–14]. These side activities are often obscured in the complex setting of a biological cell, and as such contribute little to the fitness of the organism. However, these side activities are thought of as a major source for genetic innovation: proteins can evolve the ability to use new substrates by improving an already existing, but low, side activity [15–18].

Membrane transporters form a special class of enzymes, as they generally do not break or make covalent bonds. Hence, they experience fewer constraints of the chemistry of their substrates. In principle, any small molecule can be transported through a lipid membrane. Thus, it is not surprising that life has evolved transport systems for virtually every metabolite, ion, and xenobiotic [19, 20]. In many branches of the tree of life, transporter genes underwent processes of repeated duplication and divergence, leading to extended gene families; many genomes have an array of transporter paralogs [12, 20–22]. Typically, each paralog displays a distinct substrate specificity profile, and thus a distinctly evolved function. Some notable examples of gene family expansion are found within the APC (Amino acid-Polyamine-organoCation) superfamily of transporters, which include: the neurotransmitter transporter family in animals

(20 paralogs in human, TC 2.A.22), the AAAP family in plants (58 paralogs in rice, TC 2.A.18), the AAT family in Proteobacteria (11 paralogs in *Escherichia coli*, TC 2.A.3.1), and the yeast amino acid transporter family (YAT) in fungi (18 paralogs in budding yeast, TC 2.A.3.10). The APC superfamily is the second-largest group of membrane transport proteins [23].

Most APC superfamily members are transporters for amino acids, their analogs, or related amines. Some transporters are generalists, accepting a wide range of substrates; others are considered specialists, recognizing one or a few related substrates [21, 24]. How do such patterns arise? Does the evolution of specialists move through a generalist stage? Or do new specialists evolve through switching from one specific substrate to another? For classical enzymes, many lines of evidence point to the former [8, 12, 13, 25, 26]. However, the evolution of new traits in the special case of transporters is understudied, partly because of a lack of appropriate experimental evolution methods [27].

Here, we propose that APC-type transporters can evolve novel functions through generalist intermediates, similar to classical enzymes. We showcase the presence of so far unknown substrates of five out of seven studied yeast amino acid transporters and develop a growth-based selection platform. Utilizing *in vivo* experimental evolution, under purifying selection for the original function and simultaneous selection for a new function, we evolve the substrate spectrum of two of these transporters. We show that the acquired mutations result either in improving an existing weak activity or in establishing activity for a new substrate. At the same time, each mutation has a distinct impact on the fitness of the organism for each of the transporter's original substrates.

Results

The budding yeast, *Saccharomyces cerevisiae*, typically encodes 18 members of the yeast amino acid transporter (YAT) family, each with a different substrate profile [24]. This array of transporters enables yeast to use 20 different L-amino acids as the sole nitrogen source in minimal media. These include 17 of the 20 proteinogenic amino acids (the exceptions are Cys, His, and Lys) and 3 non-proteinogenic ones [γ-amino butyric acid (GABA), L-ornithine (Orn), and L-citrulline (Cit)]. Here, we use an engineered yeast strain (Δ10AA) that lacks ten membrane transporters for amino acids [28]. This strain is thus severely deficient in the uptake of amino acids, preventing it from using most of them as the nitrogen source. When an amino acid transporter is genetically reintroduced, its substrate profile directly determines which amino acids can support growth. In the following text, the gene names are used in place of the protein names for consistency (e.g., *AGP1* instead of Agp1). The Δ10AA yeast strain expressing different transporter genes was used in all growth and transport assays.

Substrate spectrum of seven yeast amino acid transporters

We investigated the substrate profile of seven yeast amino acid transporters, by measuring the growth rates of Δ10AA strains overexpressing each transporter gene from pADHXC3GH, in the presence of 2 mM of each amino acid that served as nitrogen source. We determined growth rates in order to study each transporter's substrate range separately. For five of the seven transporters tested, we found substrates that were not previously reported in literature. These substrates were identified by significantly increased growth rates of Δ10AA expressing the respective transporter in comparison to the strain carrying the empty plasmid (vector control) (Table 1). Because of high background growth of the vector control on Arg and Orn (probably due to the activity of the *VBA5* transporter [29]), these two amino acids were excluded from further analysis. Additionally, some growth of the empty vector control was observed on Gly,

Trp, Leu, Met and Gln, which complicates the interpretation of the data. The observed growth could indicate an unknown substrate specificity of an endogenous transporter. We observed that some of the newly characterized substrates support growth rates in similar ranges as the transporter's substrates already reported in literature, while other substrates support very slow growth rates, which we call weak or promiscuous activities (Figure 1 and Figure 1–figure supplement 1).

Table 1. Substrate range of transporters used in this study.

Transporter gene	**Uniprot accession number** [30]	**Substrates described in literature (reviewed in** [24]**)**	**Substrates found in the present study**
AGP1	P25376	Ala, Asn, Asp, Cys*, Gln, Glu, Gly, His*, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, GABA	Ala, Asn, Asp, GABA, Gln, Glu, Ile, Leu, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, (Cit)
BAP2	P38084	Ala, Cys*, Ile, Leu, Met, Phe, Tyr, Val	Ala, Asn, Asp, Cit, Gln, Glu, Gly, Ile, Leu, Met, Phe, Pro, Ser, Thr, Tyr, Val
CAN1	P04817	Arg, His*, Lys*, Orn, Ser	-
HIP1	P06775	His*	-
LYP1	P32487	Lys*, Met	Ala, Asn, Met, Phe, Ser, Val
MMP1	Q12372	*S*-Methylmethionine*	Val
PUT4	P15380	Ala, Gly, Pro, GABA	Ala, GABA, Pro, Ser, Val

Only amino acids showing a significantly higher growth rate than the vector control (ANOVA with Dunnett's test against vector, $p < 0.05$) are shown. Substrates newly identified in this study are underscored. Substrates with an asterisk cannot be used as the sole N-source by *S. cerevisiae*. For *AGP1*, Cit was verified as an actual substrate in a separate experiment (Figure 4–figure supplement 2) because of a very low growth rate.



Figure 1. YAT transporters support growth on a range of amino acids. Growth rates of Δ10AA expressing one of seven different wild-type YAT genes (*AGP1*, *BAP2*, *CAN1*, *HIP1*, *LYP1*, *MMP1*, *PUT4*) from pADHXC3GH and the empty vector control on 2 mM of each

amino acid. Error bars represent the SEM ($n \geq 3$). For the respective growth curves see Figure 1–figure supplement 1. For the respective growth rates see Supplementary Dataset 1.

For example, *BAP2*, previously reported to transport seven amino acids, was found to support growth on 16 amino acids (specific growth rate μ = 0.07-0.31 h^{-1}), making it a broad range transporter. The differences on the observed growth rates on each amino acid can be explained by differences in the activity of the overexpressed transporter for these substrates or changes in the expression level of the endogenous transporter. Specifically, the 2-fold higher growth rate on Leu compared to Pro could be caused by a higher transcription rate of the endogenous transporter in the presence of Leu [31, 32]. Another transporter which showed a broader substrate range than previously reported is *PUT4*. The *PUT4* transporter was found to support fast growth on Ser (μ = 0.21 h^{-1}) and slow growth on Val (μ = 0.03 h^{-1}), in addition to the already reported transport of Ala, Gly, Pro and GABA. *AGP1*, an already known broad range transporter, additionally supports very slow growth (μ = 0.03 h^{-1}) on Cit (L-citrulline), which is lower than the growth rate on any of the previously known substrates (μ = 0.11-0.31 h^{-1}). As a comparison, growth on ammonium, which does not depend on amino acid transporters, yielded the highest measured growth rate of μ = 0.36 h^{-1} (vector control, data not shown).

Experimental evolution of membrane transporter specificity

We tested whether the substrate range of amino acid transporters could be changed by experimental evolution, either by improving promiscuous activities or by evolving towards completely new substrates. For the former, we chose to study *AGP1* under a selective pressure for Cit uptake. For the latter, we studied *PUT4* under selective pressures for uptake of Asp and Glu. For the *in vivo* evolution, the OrthoRep system was used, which allows for random mutagenesis of a gene while it is actively expressed in yeast [33, 34]. Each of the two

transporter genes was encoded on this system and introduced into the transport-deficient Δ10 strain, with additional Δ*ura3* and Δ*his3* deletions needed for selection.

To select for mutants with changed substrate specificity, we employed a dual-selection scheme: The cultures were grown in minimal medium containing a nitrogen-limiting mixture of amino acids (1 mM final concentration) to ensure low-level growth of the culture. A concentration of 3 mM of the target substrate was added in the selection for evolved mutants. We expect that nonfunctional transporters are purged from the evolving population, transporters with the original substrate range are kept in low numbers, and transporter variants with novel substrates can increase to high numbers.

The cultures of *AGP1* and *PUT4* evolution strains were passaged for multiple generations in the selective media. Colonies that supported growth on the target amino acid were isolated, and the transporter gene was sequenced and re-introduced into Δ10AA cells. Three *AGP1* variants from Cit selection and three *PUT4* variants each from Asp and Glu selection (Table 2) conferred the ability to grow on the respective amino acids (Figure 2–figure supplement 1 and Figure 2–figure supplement 2).

Table 2. Evolved *AGP1*-Cit variants and *PUT4*-Asp and -Glu variants.

Evolved variant	Nucleotide substitutions	Amino acid substitutions	Abbreviated names of site-directed mutants
AGP1-Cit1	T117C T1001A T1191A A1234G T1329C C1461G T1899C	I334N (= **N**) I412V (= **V**)	*AGP1*-N *AGP1*-V *AGP1*-NV
AGP1-Cit3	T117C A308G T915C T1001A C1451G C1461G T1684C	D103G I334N (= **N**) A484G (= **G**) F562L	*AGP1*-G *AGP1*-T
AGP1-Cit11	T111C T121C G1450A A1609G	S41P A484T (= **T**) I537V	
PUT4-Asp1	T620C T1474C	L207S (= **S**) F492L	*PUT4*-S
PUT4-Asp2	T620C T1415C T1474C	L207S (= **S**) V479A F492L	
PUT4-Asp3	T191C T620C C734T G956A	I64T L207S (= **S**) S245F G319D	
PUT4-Glu1	G225A T620C	L207S (= **S**)	
PUT4-Glu2	T191C T620C G956A	I64T L207S (= **S**) G319D	
PUT4-Glu3	T191C T620C	I64T L207S (= **S**)	

Each evolved *AGP1* variant had multiple nonsynonymous mutations, most of which occurred in the predicted transmembrane part of the protein (Figure 2 and Figure 2–figure supplement 3). In two of the three variants, the I334N (transmembrane helix TM6) mutation was found. The I334 position is located at the permeation pathway of the protein as predicted from AlphaFold [35]. A mutation in position A484 (TM10) was found in two variants (A484G and A484T). Additionally, mutations were found at the intracellular N-terminus (S41P, D103G) and the predicted transmembrane helices further away from the permeation pathway (I537V in TM11, F562L in TM12).



Figure 2. Positions of the substituted amino acids investigated in this study. Side and top views of the AlphaFold models of *AGP1* (AF-P25376) (A) and *PUT4* (AF-P15380) (B) visualized in ChimeraX (1.3.0) [36]. The amino acids of interest are highlighted in different colors. The respective TMs are presented in circles. The predicted substrate binding site is represented as dashed circle.

Most *PUT4* variants had multiple nonsynonymous mutations, again mostly in the predicted transmembrane part of the protein (Figure 2 and Figure 2–figure supplement 3). Interestingly, each variant from both Asp and Glu selections had the same L207S mutation (TM3). Overlay of homologous and structurally similar proteins indicates that this position is structurally conserved and part of the substrate-binding site of the transporter (Figure 2–figure supplement 4) [37]. A change from a large hydrophobic residue to a small hydrophilic residue is thus expected to considerably change the properties of the substrate-binding site. Furthermore, in two of the three variants from Asp selection, the F492L mutation (TM10) was found. Mutations were also found at the intracellular N-terminus (I64T), between TM4 and TM5 (S245F), in TM6 (G319D), and in TM10 (V479A).

Single mutations are sufficient for altered substrate specificity

We wondered whether the altered substrate specificities could be conferred by single mutations. We made site-directed mutations in the wild-type transporter genes and tested the variants for uptake of Cit (*AGP1*) and Asp/Glu (*PUT4*). The shorthand names for each site-directed mutant can be found in Table 2.

For the *AGP1* gene, mutations in positions that occurred multiple times were investigated (i.e., I334N, A484G, and A484T; respective abbreviations *AGP1*-N, *AGP1*-G and *AGP1*-T). Additionally, the I412V mutation was included in the study (shorthand *AGP1*-V), along with

a double mutant combining I334N and I412V (abbreviation *AGP1*-NV, recreating the genotype observed in *AGP1*-Cit1). To compare the growth of the mutants on Cit media, the growth rate of Δ10AA expressing each variant from the plasmid pADHXC3GH was measured. Strikingly, each of the variants showed a large increase in growth rate relative to the wild-type (Figure 3A). Specifically, the growth rate increased 1.9-fold for *AGP1*-N, 2.4-fold for *AGP1*-V, 3.2-fold for *AGP1*-G, and 2.4-fold for *AGP1*-T. The double mutant *AGP1*-NV showed a growth rate increase that is higher than each of its single mutants (2.8-fold). In separate uptake assays with radiolabeled Cit, we found a similar general trend of higher uptake rate of Cit by the mutants (Figure 3B); the relatively slow uptake and inherent experimental variation of the measurements prevented sound statistical analysis (Figure 3–figure supplement 1A). We thus conclude that each of the tested single mutations are adaptive for growth on Cit as the nitrogen source.



Figure 3. The evolved variants support growth and uptake of the respective amino acids. (A) Growth rate of the *AGP1* variants and the vector control on 2 mM Cit. Error bars represent the SEM (n ≥ 3). (B) Uptake rate of 1 mM ^{14}C-Cit by whole cells expressing different *AGP1* variants or none (vector control). Error bars represent the SEM (n ≥ 3). Asterisks indicate the degree of significant difference (one-way ANOVA with a Dunett's test; ** $p < 0.01$, * $p < 0.05$) between the *AGP1* variants and wild-type. (C) Growth rate of the *PUT4* variants and the vector on 2 mM Asp and Glu. Error bars represent the SEM (n ≥ 3). (D) Uptake rate of 1 mM ^{14}C-Glu by whole cells expressing different *PUT4* variants or none (vector control). Error bars represent the SEM (n ≥ 3). Asterisks indicate the degree of significant difference in pairwise

comparisons between the transporter-expressing variants (Student's t-test; ** $p < 0.01$, * $p < 0.05$).

Regarding the *PUT4* gene, we focused on the L207S single mutation since it occurred in all evolved variants (mutant abbreviation *PUT4*-S). The growth rates of Δ10AA expressing either the wild-type or the *PUT4*-S variant from pADHXC3GH were measured. While the wild-type transporter conferred no growth in the presence of Asp and Glu, the *PUT4*-S variant allowed growth on both of these substrates, showing that the single mutation is sufficient to change the specificity range of the transporter (Figure 3C). To confirm that the observed growth is due to transport of a novel substrate by *PUT4*-S, we conducted a whole-cell uptake assay with radiolabeled Glu. Indeed, Glu was only taken up by the mutant, whereas the wild-type *PUT4* behaved like the vector control (Figure 3D and Figure 3–figure supplement 1B).

Single mutations have distinct impacts on the fitness for the original substrates

Above, we established that amino acid transporters can be evolved towards new specificity or increased activity of a substrate by just one mutation. Next, we wanted to know how these adaptive mutations affect the original substrate range and specificity of the transporters. Are the original substrates still transported by the variants? And if so, how does the transport compare to the wild-type? For that, we compared the fitness effects of the *AGP1* and *PUT4* variants for their respective substrates. The relative fitness of each mutant in the studied media was calculated from the growth rate of yeast expressing that mutant, normalized to the growth rate of yeast expressing the wild-type transporter. Additionally, we measured the uptake rates

of a set of original substrates in whole cells to investigate if the growth fitness effects were due to changed transport activity.

For the *AGP1* variants, we measured growth rates for 17 substrates (Figure 4 and Figure 4–figure supplement 1-S8) and found that none of the single and double mutants had lost the capacity to grow on any of the original substrates. As a general trend, the *AGP1* variants had a lower fitness than the wild-type, although some had a higher fitness for a given substrate.



Figure 4. Relative fitness of evolved *AGP1* variants. (A) Relative fitness of *AGP1* variants and the control strain for the growth on each of 17 amino acids as the sole nitrogen source. The relative fitness was calculated separately for each amino acid by dividing the growth rate of the mutant by the mean growth rate of the wild-type *AGP1*. Error bars represent the SEM ($n \geq 3$). For the respective growth curves see Figure 4–figure supplement 1. (B) Mean relative fitness of *AGP1* variants per substrate as a function of the amino acid hydropathy index (x axis) and molecular volume (y axis). Color corresponds to relative fitness. The plot is based on the growth rate measurements of panel (A).

The *AGP1* variants had different growth rates on the original substrates (Table 3 and Figure 4B). The amino acid substitutions I334N and I412V had a different effect on the relative fitness depending whether they were analyzed individually or together in the double mutant. Specifically, the *AGP1*-V variant showed significantly increased relative fitness on GABA as nitrogen source, while showing no significant differences in any of the other substrates. The *AGP1*-N variant showed decreased relative fitness on the negatively charged amino acids Asp and Glu, as well as on Ala. The double mutant *AGP1*-NV showed decreased relative fitness on the majority of the tested amino acids (a total of 12 out of 17), including the ones in which the single mutant *AGP1*-N also exhibited decreased relative fitness. Interestingly, the *AGP1*-NV did not show significantly increased relative fitness in GABA, in contrast to *AGP1*-V. Despite the higher relative fitness of the double mutant on Cit (2.8) compared to that of the single mutants, the variant's low relative fitness on the rest of the amino acids has a greater cost on the overall fitness of that strain (0.78). Also, the observed mistargeting of the transporters to internal membranes in the cases of *AGP1-N* and *AGP1-NV* could indicate misfolding of a fraction of the proteins, which could impact the relative fitness (Figure 5A).

Table 3. Substrates of *AGP1* strains with statistically significant relative fitness differences.

AGP1 variant	Substrates with significantly increased relative fitness	Substrates with significantly decreased relative fitness	Overall relative fitness (mean of 17 original substrates)	Relative fitness on Cit
AGP1-N		Ala, Asp, Glu	0.92	1.9
AGP1-V	GABA		0.98	2.4
AGP1-NV		Ala, Asn, Asp, Glu, Ile, Leu, Met, Phe, Pro, Ser, Thr, Tyr	0.78	2.8
AGP1-G	GABA		1.0	3.2
AGP1-T		Asp, Gln, Glu, Ile, Leu, Met, Phe, Thr, Val	0.86	2.4

One-Way ANOVA with a Dunnett's test with *AGP1* wild-type as the control group was used with a cutoff of $p < 0.05$. Overall relative fitness estimates are calculated from the mean of growth rates on 17 original substrates relative to the wild-type.



Figure 5. Effects of evolved *AGP1* mutations on the growth and uptake of original substrates. (A) Localization of the *AGP1* variants in whole cells by fluorescence microscopy. (B) Growth rate of the *AGP1* variants and the vector on 2 mM Glu. Error bars represent the SEM ($n \geq 3$). (C-D) Uptake rate of 0.1 (C) and 2 mM (D) ^{14}C-Glu in whole cells expressing

different *AGP1* variants or none (vector control). In the case of *AGP1*-G, the assay was performed with 2 mM ^{3}H-Glu and is presented as independent experiment. Error bars represent the SEM (n ≥ 3). (E) Growth rate of the *AGP1* variants and the vector control on 2 mM Phe. Error bars represent the SEM (n ≥ 3). (F-G) Uptake rate of 0.1 (F) and 2 mM (G) ^{14}C-Phe in whole cells expressing different *AGP1* variants or none (vector control). Error bars represent the SEM (n ≥ 3). Asterisks indicate the degree of significant difference (one-way ANOVA with a Dunett's test; ** $p < 0.01$, * $p < 0.05$) between the *AGP1* variants and wild-type. For the respective uptake curves see Figure 5–figure supplement 1.

The fitness effects were drastically different between *AGP1*-G and -T, both having A484 substituted. The *AGP1*-G variant showed significantly increased relative fitness on GABA and a trend of overall increased relative fitness on small aliphatic amino acids of intermediate hydrophilicity (Pro, Gly). Simultaneously, its relative fitness on Cit was higher than any of the other mutants. *AGP1*-T showed mainly negative relative fitness effects, with decreased relative fitness for charged amino acids and the majority of non-polar amino acids (a total of 9 out of 17).

The idea that the observed fitness effects are due to changed transport activity and/or affinity constant for the substrate was investigated by measuring the uptake rates of radiolabeled Phe and Glu. The uptake was measured at two different amino acid concentrations, namely 0.1 mM and 2 mM, which are respectively lower and higher than the K_m of the wild-type protein for amino acids [K_m = 0.2-0.79 mM (reviewed in [24])] (Figure 5 and Figure 5–figure supplement 1). For Glu it was found that the uptake rates at both concentrations (Figure 5C and D) correlate well with the relative fitness. An almost identical pattern was observed when the uptake and the growth rates of the variants were compared at 2 mM Glu (Figure 5B and D). The fact that

AGP1-N, *AGP1*-NV and *AGP1*-T showed a pattern of both reduced growth rate and reduced uptake rate compared to the wild-type indicates that the relative fitness indeed is linked to the activity of the transporter. Equivalently, in the case of Phe as nitrogen source, the relative fitness and uptake rate of the *AGP1* variants followed similar trends. At 2 mM Phe, the effects on uptake were almost congruent to the growth rates (Figure 5E and G). The reduced uptake and growth rate of *AGP1*-NV compared to the wild-type indicates that the lower fitness of the *AGP1*-NV on Phe possibly stems from its reduced transport rate, but an effect of the internalization of the transporter cannot be excluded (Figure 5A).

The growth rates of Δ10AA expressing *PUT4* and *PUT4*-S showed that the mutation affects considerably the relative fitness of the strain in three of the original substrates (Figure 6B). Specifically, *PUT4*-S was associated with a significant fitness loss during growth on 2 mM Ala and GABA, and a fitness gain in Val. To investigate the phenotype further, we followed the uptake of radiolabeled Ala and GABA at a concentration of 10 μM, well below the reported K_m (reviewed in [24]) (Figure 6 and Figure 5–figure supplement 2). As with *AGP1* variants, the relative fitness and uptake rate trends coincided, indicating that the slower amino acid uptake may cause the slower growth of *PUT4*-S on both Ala and GABA (Figure 6C and D). Additionally, we investigated the uptake of Gly, another known substrate of *PUT4*. Due to high background growth of the Δ10AA strain on Gly, there was no significant difference in the growth rates between *PUT4*-expressing and vector control cultures. However, the uptake assays showed a clear transport activity of the wild-type *PUT4* strain, which decreased dramatically in the case of *PUT4*-S (Figure 6E). There is thus a clear cost of the mutation on the uptake of Gly.



Figure 6. Effects of evolved *PUT4*-S mutation on the growth and uptake of original substrates. (A) Localization of the *PUT4* variants in whole cells by fluorescence microscopy. (B) Relative fitness of *PUT4*-S and the vector for the growth on 6 amino acids as the sole nitrogen source. The relative fitness was calculated separately for each amino acid by dividing the growth rate of the mutant by the mean growth rate of the wild-type *PUT4*. Error bars represent the SEM ($n \geq 3$). For the respective growth curves see Figure 4–figure supplement 1. (C-E) Uptake rate of 10 μM ^{14}C-Ala (C), GABA (D) or Gly (E) in whole cells expressing *PUT4* variants or none (vector). Error bars represent the SEM ($n \geq 3$). Asterisks indicate the degree of significant difference in pairwise comparisons between the transporter-expressing variants

(Student's t-test; ** $p < 0.01$, * $p < 0.05$). For the respective uptake curves see Figure 5–figure supplement 2.

The wild-type transporter supported very slow growth on Val ($\mu = 0.03\ h^{-1}$) and we therefore consider its transport a promiscuous activity. This coincides with the larger size and hydrophobicity of the Val molecule relative to Ala, GABA, Gly, Pro and Ser. For Val, the fitness of *PUT4*-S was dramatically increased compared to wild-type (2.4-fold), which could be explained with the predicted size increase of the substrate-binding site of the transporter (see above). Thus, the gain-of-function mutation L207S affected the transport of at least four original substrates, three of which negatively, and one positively.

Single mutations can significantly broaden the substrate range of amino acid transporters

All variants with increased fitness for one substrate can still transport the wild-type's original substrates. For *AGP1*, each of the four tested single mutants as well as the double mutant retained the ability to confer growth on all amino acids that we tested.

Similarly, for *PUT4*, the L207S mutation added transport of Glu and Asp, while still retaining the ability to transport the original substrates Ala, GABA, Gly, Pro, Ser, and Val. Since we established that one single evolutionary mutation extended the strain's growth by two additional amino acids, we wondered whether this mutation also impacted the overall substrate range of the transporter. Therefore, growth assays for the *PUT4*-S strain were conducted with 18 amino acids (Figure 7A). Remarkably, the transporter variant conferred growth on 15 of the studied substrates. Specifically, the evolved variant transports Asp and Glu (the amino acids used for the initial selection), as well as Asn, Cit, Gln, Thr, Ile, Leu and Met in addition to the

six substrates of the wild-type transporter *PUT4*. Regarding the growth on Gln, we note that although the growth rates of *PUT4*-S and *PUT4* were not significantly different, the shape of the growth curve implies that Gln is indeed taken up (Figure 4–figure supplement 1). In the case of growth on Phe and Trp, the results were not conclusive due to the high background growth of the vector control strain.



Figure 7. The evolved *PUT4*-S mutation broadens the substrate range of the transporter. (A) Growth rate measurements of *PUT4* variants and the vector control on 2 mM of 18 different

amino acids as the sole nitrogen source. Error bars represent the SEM ($n \geq 3$). Asterisks indicate the degree of significant difference in pairwise comparisons (Student's t-test; ** $p < 0.01$, * $p < 0.05$). For the respective growth curves see Figure 4–figure supplement 1. (B) Mean relative fitness of *PUT4*-S per substrate as a function of the amino acid hydropathy index (x axis) and molecular volume (y axis). Diamond shapes indicate novel substrates not found in the wild-type *PUT4*. Color corresponds to relative fitness. The plot is based on the same growth rate measurements as (A).

Upon grouping the amino acids according to their size and hydropathy index [38, 39], a clear trend emerged for the novel substrates of *PUT4*-S. In addition to the small substrates of low and intermediate hydrophilicity, the evolved variant facilitates the uptake of larger hydrophobic amino acids (Ile, Leu, Met) as well as hydrophilic amino acids (Thr, Asp, Asn, Gln, Glu, Cit) (Figure 7B, colored area 2 and 1 respectively). Thus, we showcase that a single adaptive mutation is sufficient to evolve a narrow-range transporter (*PUT4*: 6 substrates) to a broad-range transporter (*PUT4*-S: 15 substrates).

Discussion

Different theoretical models have been developed to explain the origin of new functions in proteins. Many favor the idea that new functions are acquired prior to gene duplication while the original functions are maintained [11]. While these models have been used to describe the evolution of functions in soluble enzymes, we showcase that the theory also applies to membrane transporters. To simulate natural transporter evolution, we evolved *in vivo* two yeast amino acid transporters, *AGP1* and *PUT4*, with selective pressure for transport of novel substrates.

We show that the substrate spectrum of five wild-type yeast amino acid transporters is substantially broader than previously described. The use of a growth-based screening process enabled us to identify so far unknown substrates (up to nine in the case of *BAP2*). The transporter genes were expressed from a multicopy plasmid (2μ origin of replication), where the number of plasmid copies that each daughter cell receives is stochastic [40]. Cells with different copy numbers could potentially have an advantage in our growth rate-based measurements of transporter activity. Thus, the mean copy number of the culture is expected to change during the 3-day cultivation period. The growth rate is therefore a measure of the fitness of the strain when the transporter gene copy number is optimized, which is probably the reason why the growth-based assay is so sensitive for promiscuous transporter activities that have not been described before.

It is apparent that the relative fitness of each strain expressing a transporter depends on the amino acid provided. For the strain expressing *AGP1*, Cit supports very low growth rates indicative of a promiscuous uptake activity by *AGP1* that has not been reported previously. We show that upon the presence of selective pressure for the uptake of Cit, this weak transport activity of *AGP1* is increased by adaptive mutations. Each of the five studied mutants resulted in a gain of relative fitness for growth on Cit. The differential Cit uptake rates of the single and double mutants showcase how *in vivo* experimentally generated single mutations can alter the substrate spectrum of the yeast amino acid transporters without the loss of ancestral functions. Our observations are in line with studies of substrate promiscuity being the result of adaptive mutations in different membrane transporters [41–47]. The altered specificity for a substrate, which is mirrored in our case in the altered fitness, could be a result of a different affinity constant for the amino acid and/or maximal transport rate.

We also established that through applying evolutionary pressure upon the *PUT4* membrane transporter, single mutations can emerge in the population which provide a gain of function.

The newly obtained function is essential for the survival of the organism in the new environment. Interestingly, the same mutation (L207S) in the *PUT4* gene was found when evolutionary pressure was applied for the growth on media supplemented with either Asp or Glu as the sole nitrogen source. The L207 residue is predicted to be part of the substrate-binding site of the transporter. Thus, the replacement of the large hydrophobic leucine residue with a small hydrophilic serine residue is likely to increase both the size and the hydrophilicity of the binding pocket. This could be the reason that the evolved transporter now facilitates the uptake of hydrophilic as well as large hydrophobic amino acids.

In both *AGP1* and *PUT4*, the evolved variants retain their original substrate spectrum albeit with altered specificities. Our results showcase that specific adaptive mutations for a novel substrate often decrease the fitness for the original substrates, creating a situation of trade-off between new and old function. However, in some cases, the fitness for single original substrates actually increases (e.g., *AGP1*-G and *AGP1*-V for GABA, or *PUT4*-S for Val). Depending on the environment, a mutation can thus be adaptive for multiple substrates at the same time, including ones that were not selected for. For evolution on Cit, the mutant with the highest fitness gain (*AGP1*-G) showed no loss of relative fitness for the original substrates. Thus, this mutation could potentially occur in the population even without the presence of Cit as selective pressure or even outcompete others in a natural setting where the selective pressure is applied. On the contrary, the combination of two adaptive mutations (*AGP1*-NV) had a higher fitness cost for original substrates than the separate mutations, but also a higher fitness gain for the novel substrate. Thus, in a natural setting, such a variant would only be viable if the novel substrate gives a very high selective advantage as compared to the original ones. Alternatively, gene duplication could lead to two distinct transporter genes, one specializing in the novel substrate, while the other (re-)specializes for the original substrates [11].

Taken together, our findings show that transporters can have promiscuous weak activities, which are often hidden in the natural context of the cell. Furthermore, transporters can evolve novel substrates through generalist intermediates, either by increasing a weak activity or by establishing a new one. Looking at single adaptive mutations, we quantify the fitness trade-off between novel and original substrates, indicating that each mutation impacts the original substrates differently. Thus, depending on the ratio of the selective pressure for the original and novel functions, different mutations might be selected and outcompete others in the population. Overall, we show how transporter evolution could help organisms to explore ecological niches where novel transport activities give a fitness benefit, while still retaining the ability to thrive in the old environment.

Methods

Media

S. cerevisiae strains were grown in YPD medium (Formedium; nonselective medium, autoclaved), YNB medium (6.9 g/L yeast nitrogen medium without amino acids (Formedium) + 20 g/L glucose; selective medium, sterile filtered) or YB medium (1.9 g/L YNB without amino acids and without ammonium sulfate (Formedium) + 20 g/L glucose; selective medium without nitrogen source, sterile filtered). To supplement specific nitrogen sources to YB media, stock solutions were prepared by filter sterilization.

For *in-vivo* evolution, the following media were used: Cit evolution medium (YB supplemented with Ala, Asn, Asp, GABA, Gln, Glu, Gly, Ile, Leu, Met, Orn, Phe, Pro, Ser, Thr, Trp, Val at 60 µM each and Cit at 3.06 mM), Asp evolution medium (YB supplemented with Pro, GABA at 0.5 mM each and Asp at 3 mM), Glu evolution medium (YB supplemented with Pro, GABA at 0.5 mM each and Glu at 3 mM). The amino acids were purchased from Sigma-Aldrich.

DNA plasmid construction

The plasmids used in this study are listed in Table 4. Cloning was performed with standard molecular biology methods; pADHXC3GH and its derivatives were constructed via Gibson assembly [48] and FX cloning [49]. Site-directed mutagenesis [50] was also achieved by Gibson assembly, using gene-specific primers with base changes at the position of interest. The single-mutation genes were assembled from the plasmid backbone and two separate PCR fragments, while the double-mutation *AGP1*-NV variant was assembled from three PCR fragments. Plasmids were transformed and amplified in *Escherichia coli* DB3.1 strain. Individual clones were picked, grown to saturation in antibiotic selective LB or TB liquid media, mini-prepped and sequence confirmed by Sanger sequencing [51] (Eurofins Genomics). Plasmid sequences are available in Supplementary File 1.

Table 4. List of plasmids used in this study

Plasmid name	Description	Source
FDP-P10B2-A75-RZ-URA3	Plasmid containing the integration cassette for p1, the 10B2 artificial promoter, a hardcoded poly-A tail, and an *URA3* selection marker	Gift from Chang Liu (Addgene plasmid # 130874)
FDP-*AGP1YPet*	Integration cassette for p1; derived from FDP-P10B2-A75-RZ-URA3, where the *mKate* gene was replaced by *AGP1* with an N-terminal YPet fluorescent tag	This study
FDP-*PUT4YPet*	Integration cassette for p1; derived from FDP-P10B2-A75-RZ-URA3, where the *mKate* gene was replaced by *PUT4* with an N-terminal YPet fluorescent tag	This study

pAR-Ec611	Error-prone TP-DNA polymerase 1	Gift from Chang Liu (Addgene plasmid # 130872)
pYEXC3GH	*S. cerevisiae* expression vector for FX cloning	Gift from Raimund Dutzler & Eric Geertsma (Addgene plasmid # 49027)
pADHXC3GH	Derived from pYEXC3GH, where the *GAL1* promoter was exchanged for the constitutive *S. cerevisiae ADH* promoter. The *GOI* is expressed as a fusion protein with N-terminal 3C cleavage site, yeGFP, and His_{10} tag.	This study
pADHXC3GH-*AGP1*		This study
pADHXC3GH-*BAP2*		This study
pADHXC3GH-*CAN1*		This study
pADHXC3GH-*HIP1*		This study
pADHXC3GH-*LYP1*		This study
pADHXC3GH-*MMP1*		This study
pADHXC3GH-*PUT4*		This study
pADHXC3GH-*AGP1*-N	*T1001A* = I334N	This study
pADHXC3GH-*AGP1*-V	*A1234G* = I412V	This study
pADHXC3GH-*AGP1*-NV	*T1001A*, *A1234G* = I334N, I412V	This study
pADHXC3GH-*AGP1*-G	*C1451G* = A484G	This study
pADHXC3GH-*AGP1*-T	*G1450A* = A484T	This study
pADHXC3GH-*PUT4*-S	*T620C* = L207S	This study

Yeast Strains and Transformation

The yeast strains used in this study are listed in Table 5. Yeast transformations were performed as described [52]. DNA extraction from yeast strains was performed by using glass beads. Briefly, cells were washed with 250 µL of sterile water, pelleted and resuspended in 30 µL Zymolyase 20T (80 ug in total). Glass beads of 0.55 m diameter were added in 1:1 v/w ratio of Zymolyase to glass beads. The samples were incubated at 37 ºC for 30 minutes and vortexed for 1 min at maximum speed. Subsequently, they were incubated at 95 ºC for 5 minutes and cooled down on ice for 5 minutes. Finally, the cellular debris was pelleted and the supernatant could be used later on. Confirmation of the presence of the desired gene variant was performed by PCR amplification of the region of interest and subsequent Sanger sequencing (Eurofins Genomics).

Since the OrthoRep system requires two auxotrophic markers in the strain used for *in vivo* evolution [33], the Δ10AA strain was modified by complete deletion of the *ura3-1* and *HIS3* open reading frames to yield the strain Δ10ΔUH. Using Δ10ΔUH, the *in vivo* evolution strains for *AGP1* and *PUT4* were constructed essentially as described in [53]. Briefly, *S. cerevisiae* Δ10ΔUH was transformed with pAR-Ec611 containing the error-prone TP-DNA polymerase1. In parallel, the gene of interest was cloned into the FDP-P10B2-A75-RZ-URA3 plasmid containing the integration cassette for the linear cytoplasmic plasmid p1. This cassette was excised by digestion with *ScaI* and used for transformation of *S. cerevisiae* GA-Y319 (p1 manipulation strain). The recovered transformants were screened for recombinant p1 plasmids containing the gene of interest by PCR (*GOI*) and by agarose gel electrophoresis of complete DNA extracts. A positive colony was picked and used to transfer the recombinant p1 along with wild-type p2 into Δ10ΔUH pAR-Ec611 to yield the strains Δ10ΔUH evol-*AGP1* and evol-*PUT4*.

Table 5. *S. cerevisiae* strains used in this study.

Strain name	Genotype	Source
Δ10AA (original name 22Δ10AAα)	*MAT**a*** gap1-1 put4-1 uga4-1 Δcan1::HisG Δlyp1-alp1::HisG Δhip1::HisG Δdip5::HisG Δgnp1 Δagp1 ura3-1*	Gift from Guillaume Pilot [28]
Δ10ΔUH	*MAT**a*** gap1-1 put4-1 uga4-1 Δcan1::HisG Δlyp1-alp1::HisG Δhip1::HisG Δdip5::HisG Δgnp1 Δagp1 Δura3*::loxP Δhis3::kanMX	This study Derived from Δ10AA
Δ10ΔUH pAR-Ec611	Δ10ΔUH pAR-Ec611 (*HIS3*)	This study
Δ10ΔUH evol-*AGP1*	Δ10ΔUH pAR-Ec611 (*HIS3*) + p1::*AGP1YPet* (*URA3*) + p2	This study
Δ10ΔUH evol-*PUT4*	Δ10ΔUH pAR-Ec611 (*HIS3*) + p1::*PUT4YPet* (*URA3*) + p2	This study
Δ10AA pADHXC3GH-*GOI*s	Strains containing the pADHXC3GH plasmids containing various genes of interest, see plasmids	This study
GA-Y319	MAT**a** *can1 his3 Δleu2 Δura3 Δtrp1 flo1* + p1 + p2	Gift from Chang Liu

* The original 22Δ10AAα strain was labeled as *MATα*, but was found to be *MAT**a*** in our laboratory (data not shown).

In vivo evolution

AGP1: A culture of Δ10ΔUH evol-*AGP1* was grown at 30 °C for ca. 100 generations (14 passages, reinoculating 1:200) in 10 mL Cit evolution medium. At two time points, single colonies that were able to use Cit as the sole N-source were isolated by plating on YB + 1 mM Cit agar dishes. To confirm the genotype–phenotype linkage, the evolved *AGP1* variants were cloned into the pADHXC3GH expression vector, sequenced, and introduced into naïve Δ10AA cells.

PUT4: Parallel cultures of Δ10ΔUH evol-*PUT4* were grown at 30 °C for ca. 33 generations (5 passages, re-inoculating 1:100) in 2 mL Asp or Glu evolution medium or control medium without an additional nitrogen source. Thereafter, the growth on media containing Asp or Glu only (YB + Asp or Glu at 3 mM, no other nitrogen sources) was compared to the control cultures. These cultures were used to clone the bulk of *PUT4* variants into the pADHXC3GH expression vector and introduced into naïve Δ10AA cells. Transformants were plated on YB + Asp 1 mM or YB + Glu 1 mM agar dishes, and colonies showing growth on these selective media were used for sequencing.

Growth assay

Single colonies of *S. cerevisiae* Δ10AA pADHXC3GH-*GOI* were inoculated in YB media supplemented with 4 mM NH_4^+ and 0.1 mg/mL ampicillin, and grown until late logarithmic phase. The cultures were pelleted at 750 × *g* for 10 min at 30 °C and washed with YB media. The wells in the microplate were filled with the amino acids of interest to a final concentration of 2 mM and with culture cells to a final OD_{600} of 0.04, to a final total well volume of 200 µL. Sterile water was added in the space between the wells to avoid evaporation. The prepared microplates included three biological replicates of the strains with the plasmid containing the *GOI* and one biological replicate of the strain with the empty vector. The absorbance in each well was measured at 600 nm in 30 min intervals without shaking of the microplate, at 30 °C for 72 h in a SpectraMax ABS Plus plate reader. Data are shown in this report as the specific growth rate for each biological replicate and the error bars describe the SEM. The growth rates were derived based on the Baranyi growth model [54], using the *growthrates* package in *R*. The Huang model [55, 56] was also tested, but deemed less suitable because of the higher number of interdependent parameters, which consumes part of the fitness effects. The code and raw data are available in Supplementary File 1.

In vivo transport assay

Single colonies of *S. cerevisiae* Δ10AA/pADHXC3GH-*GOI* were inoculated in YB media supplemented with 4 mM NH_4^+, and grown until stationary phase. Amount of the grown cultures was used to inoculate YB media supplemented with 3 mM urea so that OD_{600} is 0.05, and grown until mid-logarithmic phase. The cultures were pelleted at 750 × *g* for 10 min at 4 °C and washed with either 100 mM KPC buffer (10 mM Glucose, 100 mM K_2HPO_4, Citric acid buffer, pH 5) in the case of subsequent uptake assays with Phe, Glu and Cit, or 100 mM KP buffer (10 mM Glucose, 13.4 mM K_2HPO_4, 86.8 mM KH_2PO_4, pH 6) in the case of subsequent uptake assays with Ala, GABA and Gly. The washed cells were diluted in the respective ice-cold buffer at a final OD_{600} of 0.56–1.05.

Prior to the assay, the cells were pre-warmed in a 30 °C water bath for 5–10 min, and the uptake reactions were started by adding radiolabeled amino acid (PerkinElmer). For the uptake assays by *PUT4* variants, 1.1 μCi/mL of ^{14}C-Glu at a final concentration of 1 mM, or 0.2 μCi/mL of one ^{14}C-labeled amino acid (Ala, GABA, Gly) at a final concentration of 10 μM was added. For the uptake assays by *AGP1* variants, 0.9 μCi/mL of ^{14}C-Cit at a final concentration of 1 mM, or 0.5 μCi/mL of one ^{14}C-labeled amino acid (Phe, Glu) at a final concentration of 0.1 mM or 2 mM was added. The uptake of 2 mM Glu by the *AGP1*-G variant was performed with the addition of 4.5 μCi/mL of ^{3}H-Glu at a final concentration of 2 mM. The cells were mixed by magnetic stirring and, at given time intervals, 100 μL samples were collected and rapidly filtered on a 0.45 μM pore size nitrocellulose filter, which was subsequently washed with a total 4 mL ice-cold buffer. The filters were dissolved in 2 mL scintillation solution and vortexed before determining the radioactivity by liquid scintillation counting on a Tri-Carb 2800TR liquid scintillation analyzer (PerkinElmer).

For the calculation of the uptake rates in amol/(cell × min), the determination of the cell number was based on the translation of the OD_{600} measurements to number of cells by counting on a Thoma counting chamber. The null hypothesis that the mean of the uptake rate of the *AGP1* wild-type variant is not different from that of the mutants was tested by using the one-way ANOVA [57], and in the cases of a $p < 0.05$, the Dunnett's significance test [58] was performed (significance shown as asterisks). For the *PUT4* analysis, the null hypothesis was tested by using Student's t-test [59] ($p < 0.05$).

Localization assay

Living cells were washed in Isotope Buffer as described above and placed on a slide. The fluorescence cell imaging was performed on a Zeiss LSM 710 confocal laser scanning microscope, equipped with a C-Apochromat 40x/1.2 NA objective with a blue argon ion laser (488 nm). Images were obtained with the focal plane positioned at the mid-section of the cells.

References

1. Long M, VanKuren NW, Chen S, Vibranovski MD (2013) New Gene Evolution: Little Did We Know. Annu Rev Genet 47:307–333

2. Muller HJ (1936) Bar duplication. Science 83:528–530

3. Ohno Susumu (1970) Evolution by gene duplication. Springer-Verlag, Berlin SE - xv, 160 pages illustrations 26 cm

4. Jensen RA (1976) Enzyme recruitment in evolution of new function. Annu Rev Microbiol 30:409–425

5. Lynch M, Force A (2000) The probability of duplicate gene preservation by subfunctionalization. Genetics 154:459–473

6. Bergthorsson U, Andersson DI, Roth JR (2007) Ohno's dilemma: Evolution of new genes under continuous selection. Proc Natl Acad Sci U S A 104:17004–17009

7. Hughes AL (1994) The evolution of functionally novel proteins after gene duplication. Proc Biol S 119–124

8. Aharoni A, Gaidukov L, Khersonsky O, Gould SMQ, Roodveldt C, Tawfik DS (2005) The "evolvability" of promiscuous protein functions. Nat Genet 37:73–76

9. Des Marais DL, Rausher MD (2008) Escape from adaptive conflict after duplication in an anthocyanin pathway gene. Nature 454:762–765

10. Näsvall J, Sun L, Roth JR, Andersson DI (2012) Real-time evolution of new genes by innovation, amplification, and divergence. Science (1979) 338:384–387

11. Soskine M, Tawfik DS (2010) Mutational effects and the evolution of new protein functions. Nat Rev Genet 11:572–582

12. Copley SD, Newton MS, Widney KA (2023) How to Recruit a Promiscuous Enzyme to Serve a New Function. Biochemistry 62:300–308

13. Khersonsky O, Tawfik DS (2010) Enzyme promiscuity: A mechanistic and evolutionary perspective. Annu Rev Biochem 79:471–505

14. Andorfer MC, Grob JE, Hajdin CE, Chael JR, Siuti P, Lilly J, Tan KL, Lewis JC (2017) Understanding Flavin-Dependent Halogenase Reactivity via Substrate Activity Profiling. ACS Catal 7:1897–1904

15. Janssen DB, Dinkla IJT, Poelarends GJ, Terpstra P (2005) Bacterial degradation of xenobiotic compounds: Evolution and distribution of novel enzyme activities. Environ Microbiol 7:1868–1882

16. Jørgensen ME, Xu D, Crocoll C, Ramírez D, Motawia MS, Olsen CE, Nour-Eldin HH, Halkier BA (2017) Origin and evolution of transporter substrate specificity within the NPF family. Elife 6:1–31

17. Caligiore F, Zangelmi E, Vetro C, Kentache T, Dewulf JP, Veiga-da-Cunha M, Van Schaftingen E, Bommer G, Peracchi A (2022) Human cytosolic transaminases: side activities and patterns of discrimination towards physiologically available alternative substrates. Cellular and Molecular Life Sciences 79:1–17

18. Zheng J, Guo N, Wagner A (2020) Selection enhances protein evolvability by increasing mutational robustness and foldability. Science 370, eabb5962 (2020)

19. Saier MH, Reddy VS, Tamang DG, Västermark Å (2014) The transporter classification database. Nucleic Acids Res 42:251–258

20. Saier MH, Reddy VS, Moreno-Hagelsieb G, et al (2021) The transporter classification database (TCDB): 2021 update. Nucleic Acids Res 49:D461–D467

21. Jack DL, Paulsen IT, Saier J (2000) The amino acid/polyamine/organocation (APC) superfamily of transporters specific for amino acids, polyamines and organocations. Microbiology (N Y) 146:1797–1814

22. Perland E, Fredriksson R (2017) Classification Systems of Secondary Active Transporters. Trends Pharmacol Sci 38:305–315

23. Vastermark A, Wollwage S, Houle ME, Rio R, Saier MH (2014) Expansion of the APC superfamily of secondary carriers. Proteins: Structure, Function and Bioinformatics 82:2797–2811

24. Bianchi F, van't Klooster JS, Ruiz SJ, Poolman B (2019) Regulation of Amino Acid Transport in Saccharomyces cerevisiae. Microbiology and Molecular Biology Reviews 83:1–38

25. Risso VA, Gavira JA, Mejia-Carmona DF, Gaucher EA, Sanchez-Ruiz JM (2013) Hyperstability and substrate promiscuity in laboratory resurrections of precambrian β-lactamases. J Am Chem Soc 135:2899–2902

26. Mascotti ML, Kumar H, Nguyen QT, Ayub MJ, Fraaije MW (2018) Reconstructing the evolutionary history of F420-dependent dehydrogenases. Sci Rep 8:1–10

27. Bali AP, Genee HJ, Sommer MOA (2018) Directed Evolution of Membrane Transport Using Synthetic Selections. ACS Synth Biol 7:789–793

28. Besnard J, Pratelli R, Zhao C, Sonawala U, Collakova E, Pilot G, Okumoto S (2016) UMAMIT14 is an amino acid exporter involved in phloem unloading in Arabidopsis roots. J Exp Bot 67:6385–6397

29. Shimazu M, Itaya T, Pongcharoen P, Sekito T, Kawano-Kawada M, Kakinuma Y (2012) Vba5p, a novel plasma membrane protein involved in amino acid uptake and drug sensitivity in Saccharomyces cerevisiae. Biosci Biotechnol Biochem 76:1993–1995

30. The UniProt Consortium (2023) UniProt: the Universal Protein Knowledgebase in 2023. Nucleic Acids Res 51:523–531

31. Didion T, Grauslund M, Kielland-Brandt MC, Andersen HA (1996) Amino acids induce expression of BAP2, a branched-chain amino acid permease gene in Saccharomyces cerevisiae. J Bacteriol 178:2025–2029

32. Magasanik B, Kaiser CA (2002) Nitrogen regulation in Saccharomyces cerevisiae. Gene 290:1–18

33. Ravikumar A, Arrieta A, Liu CC (2014) An orthogonal DNA replication system in yeast. Nat Chem Biol 10:175–177

34. Ravikumar A, Arzumanyan GA, Obadi MKA, Javanpour AA, Liu CC (2018) Scalable, Continuous Evolution of Genes at Mutation Rates above Genomic Error Thresholds. Cell 175:1946-1957.e13

35. Jumper J, Evans R, Pritzel A, et al (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596:583–589

36. Pettersen EF, Goddard TD, Huang CC, Meng EC, Couch GS, Croll TI, Morris JH, Ferrin TE (2021) UCSF ChimeraX: Structure visualization for researchers, educators, and developers. Protein Science 30:70–82

37. Gibrat JF, Madej T, Bryant SH (1996) Surprising similarities in structure comparison. Curr Opin Struct Biol 6:377–385

38. Kyte J, Doolittle RF (1982) A simple method for displaying the hydropathic character of a protein. J Mol Biol 157:105–132

39. Zamyatnin AA (1972) Protein volume in solution. Prog Biophys Mol Biol 24:107–123

40. Chan KM, Liu YT, Ma CH, Jayaram M, Sau S (2013) The 2 micron plasmid of Saccharomyces cerevisiae: A miniaturized selfish genome with optimized functional competence. Plasmid 70:2–17

41. Regenberg B, Kielland-Brandt MC (2001) Amino acid residues important for substrate specificity of the amino acid permeases Can l p and Gnp l p in Saccharomyces cerevisiae. Yeast 18:1429–1440

42. Tutulan-Cunita AC, Mikoshi M, Mizunuma M, Hirata D, Miyakawa T (2005) Mutational analysis of the yeast multidrug resistance ABC transporter Pdr5p with altered drug specificity. Genes to Cells 10:409–420

43. Adler J, Bibi E (2005) Promiscuity in the geometry of electrostatic interactions between the Escherichia coli multidrug resistance transporter MdfA and cationic substrates. Journal of Biological Chemistry 280:2721–2729

44. Gros Y, Schuldiner S (2010) Directed evolution reveals hidden properties of VMAT, a neurotransmitter transporter. Journal of Biological Chemistry 285:5076–5084

45. Ghaddar K, Krammer EM, Mihajlovic N, Brohée S, André B, Prévost M (2014) Converting the yeast arginine Can1 permease to a lysine permease. Journal of Biological Chemistry 289:7232–7246

46. Young EM, Tong A, Bui H, Spofford C, Alper HS (2014) Rewiring yeast sugar transporter preference through modifying a conserved protein motif. Proc Natl Acad Sci U S A 111:131–136

47. Meier G, Thavarasah S, Ehrenbolger K, Hutter CAJ, Hürlimann LM, Barandun J, Seeger MA (2023) Deep mutational scan of a drug efflux pump reveals its structure–function landscape. Nat Chem Biol 19:440–450

48. Gibson DG, Young L, Chuang R-Y, Venter JC, Hutchison CA, Smith HO (2009) Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6:343–345

49. Geertsma ER, Dutzler R (2011) A versatile and efficient high-throughput cloning tool for structural biology. Biochemistry 50:3272–3278

50. Kunkel TA (1985) Rapid and efficient site-specific mutagenesis without phenotypic selection (M13 cloning vectors/silent mutations/in vitro mutagenesis/synthetic oligonucleotides/uracil-containing DNA). Genetics 82:488–492

51. Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A 74:5463–5467

52. Gietz RD, Schiestl RH (2007) High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat Protoc 2:31–34

53. García-García JD, Joshi J, Patterson JA, Trujillo-Rodriguez L, Reisch CR, Javanpour AA, Liu CC, Hanson AD (2020) Potential for applying continuous directed evolution to plant enzymes: An exploratory study. Life 10:1–16

54. Baranyi J, Roberts TA (1995) Mathematics of predictive food microbiology. Int J Food Microbiol 26:199–218

55. Huang L (2008) Growth kinetics of Listeria monocytogenes in broth and beef frankfurters - Determination of lag phase duration and exponential growth rate under isothermal conditions. J Food Sci 73:235–242

56. Huang L (2011) A new mechanistic growth model for simultaneous determination of lag phase duration and exponential growth rate and a new Bělehdrádek-type model for evaluating the effect of temperature on growth rate. Food Microbiol 28:770–776

57. Girden ER (1992) ANOVA : repeated measures. Sage Publications, Newbury Park, Calif.

58. Dunnett CW (1955) A Multiple Comparison Procedure for Comparing Several Treatments with a Control. J Am Stat Assoc 50:1096–1121

59. Student (1908) The Probable Error of a Mean. Biometrika 6:1–25


Growth rate [h^{-1}]
Ala
Arg
Asn
Asp
Cit
GABA
Gln
Glu
Gly
Ile
Leu
Met
Orn
Phe
Pro
Ser
Thr
Trp
Tyr
Val
0.0
0.1
0.2
0.3
AGP1
BAP2
CAN1
HIP1
LYP1
MMP1
PUT4
vector


A
Side view
Top view
Extracellular side
Cytoplasmic side
I412
A484
I334
8
10
6
B
L207
9
4
3
5
2
7


A
2 mM Cit
Growth rate [h^{-1}]
0.00
0.03
0.06
0.09
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
B
1 mM Cit
Uptake rate per cell [amol/min]
0
5
10
15
20
**
*
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
C
2 mM Asp
2 mM Glu
Growth rate [h^{-1}]
0.00
0.05
0.10
0.15
PUT4
PUT4-S
vector
PUT4
PUT4-S
vector
D
1 mM Glu
Uptake rate per cell [amol/min]
0
10
20
30
40
50
*
PUT4
PUT4-S
vector


A
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
Relative fitness
0.0
0.5
1.0
1.5
Ala Asn Asp GABA Gln Glu Gly Ile Leu Met Phe Pro Ser Thr Trp Tyr Val
B
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
Molecular volume
100
150
200
Cit Tyr Phe Met Ile Leu Gln Glu Asn Pro Thr Val Asp GABA Ser Ala Gly
-2.5
0.0
2.5
Hydropathy index
Fitness
3.0
2.5
2.0
1.5
1.0


A
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
B
2 mM Glu
Growth rate [h^{-1}]
0.25
0.20
0.15
0.10
0.05
0.00
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
C
0.1 mM Glu
Uptake rate per cell [amol/min]
125
100
75
50
25
0
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
D
2 mM Glu
Uptake rate per cell [amol/min]
1500
1000
500
0
**
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-T
vector
2 mM Glu
Uptake rate per cell [amol/min]
600
400
200
0
AGP1
AGP1-G
vector
E
2 mM Phe
Growth rate [h^{-1}]
0.20
0.15
0.10
0.05
0.00
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
F
0.1 mM Phe
Uptake rate per cell [amol/min]
200
150
100
50
0
*
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector
G
2 mM Phe
Uptake rate per cell [amol/min]
1250
1000
750
500
250
0
AGP1
AGP1-N
AGP1-V
AGP1-NV
AGP1-G
AGP1-T
vector


A
PUT4
PUT4-S
B
PUT4-S
vector
Relative fitness
0
1
2
3
Ala
GABA
Gly
Pro
Ser
Val
C
10 μM Ala
Uptake rate per cell [amol/min]
0
5
10
15
20
25
**
PUT4
PUT4-S
vector
D
10 μM GABA
Uptake rate per cell [amol/min]
0
5
10
15
20
25
**
PUT4
PUT4-S
vector
E
10 μM Gly
Uptake rate per cell [amol/min]
0
2
4
6
8
**
PUT4
PUT4-S
vector


A
Ala
Asn
Asp
Cit
GABA
Gln
Glu
Gly
Ile
Leu
Met
Phe
Pro
Ser
Thr
Trp
Tyr
Val
Growth rate [h^{-1}]
0.0
0.1
0.2
0.3
0.4
**
*
ns
PUT4
PUT4-S
vector
B
PUT4-S
Molecular volume
Hydropathy index
-2.5
0.0
2.5
100
150
Cit
Gln
Glu
Asn
Asp
Pro
Thr
GABA
Ser
Gly
Met
Leu
Ile
Val
Ala
1
2
Fitness
2.0
1.5
1.0